- Home
- ERAS vs NATH Comparison
ERAS vs NATH Comparison
Compare ERAS & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- NATH
- Stock Information
- Founded
- ERAS 2018
- NATH 1916
- Country
- ERAS United States
- NATH United States
- Employees
- ERAS N/A
- NATH N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- NATH Restaurants
- Sector
- ERAS Health Care
- NATH Consumer Discretionary
- Exchange
- ERAS Nasdaq
- NATH Nasdaq
- Market Cap
- ERAS 396.6M
- NATH 385.4M
- IPO Year
- ERAS 2021
- NATH N/A
- Fundamental
- Price
- ERAS $1.43
- NATH $101.80
- Analyst Decision
- ERAS Strong Buy
- NATH
- Analyst Count
- ERAS 6
- NATH 0
- Target Price
- ERAS $4.83
- NATH N/A
- AVG Volume (30 Days)
- ERAS 1.5M
- NATH 9.2K
- Earning Date
- ERAS 05-20-2025
- NATH 06-11-2025
- Dividend Yield
- ERAS N/A
- NATH 2.00%
- EPS Growth
- ERAS N/A
- NATH 24.88
- EPS
- ERAS N/A
- NATH 5.80
- Revenue
- ERAS N/A
- NATH $146,386,000.00
- Revenue This Year
- ERAS N/A
- NATH N/A
- Revenue Next Year
- ERAS N/A
- NATH N/A
- P/E Ratio
- ERAS N/A
- NATH $17.04
- Revenue Growth
- ERAS N/A
- NATH 6.83
- 52 Week Low
- ERAS $1.01
- NATH $66.35
- 52 Week High
- ERAS $3.45
- NATH $104.96
- Technical
- Relative Strength Index (RSI)
- ERAS 52.92
- NATH 70.50
- Support Level
- ERAS $1.37
- NATH $97.97
- Resistance Level
- ERAS $1.61
- NATH $104.96
- Average True Range (ATR)
- ERAS 0.14
- NATH 2.24
- MACD
- ERAS 0.00
- NATH 0.53
- Stochastic Oscillator
- ERAS 53.09
- NATH 73.36
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.